Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC
Ping Chen, Yinfeng Li, Xiaomei Jing, Jing Chen, Shimei Chen, Qing Yang
Topics & Concepts
MedicineOncologyInternal medicineChemotherapyRegimenLung cancerCost effectivenessChemotherapy regimenPopulationnon-small cell lung cancer (NSCLC)A549 cellRisk analysis (engineering)Environmental healthLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers